In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques

Joseph F. Poduslo, Muthu Ramakrishnan, Silvina S. Holasek, Marina Ramirez-Alvarado, Karunya K. Kandimalla, Emily J. Gilles, Geoffry L. Curran, Thomas M. Wengenack

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Targeting therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood-brain barrier. We report that a F(ab′)2 fragment of a monoclonal antibody against fibrillar human Aβ42 that is polyamine (p)-modified has increased permeability at the blood-brain barrier, comparable binding to the antigen, and comparable in vitro binding to amyloid plaques in Alzheimer's disease (AD) transgenic mouse brain sections. Intravenous injection of the pF(ab′)24.1 in the AD transgenic mouse demonstrated efficient targeting to amyloid plaques throughout the brain, whereas the unmodified fragment did not. Removal of the Fc portion of this antibody derivative will minimize the inflammatory response and cerebral hemorrhaging associated with passive immunization and provide increased therapeutic potential for treating AD. Coupling contrast agents/radioisotopes might facilitate the molecular imaging of amyloid plaques with magnetic resonance imaging/positron emission tomography. The efficient delivery of immunoglobulin G fragments may also have important applications to other neurodegenerative disorders or for the generalized targeting of nervous system antigens.

Original languageEnglish (US)
Pages (from-to)420-433
Number of pages14
JournalJournal of Neurochemistry
Volume102
Issue number2
DOIs
StatePublished - Jul 2007

Fingerprint

Molecular imaging
Immunoglobulin Fragments
Molecular Imaging
Amyloid Plaques
Neurology
Nervous System Diseases
Amyloid
Immunotherapy
Alzheimer Disease
Blood-Brain Barrier
Nervous System
Transgenic Mice
Brain
Immunization
Antigens
Positron emission tomography
Passive Immunization
Polyamines
Magnetic resonance
Intravenous Injections

Keywords

  • Alzheimer's disease
  • Amyloid plaques
  • Antibody fragments
  • Contrast agent
  • Molecular imaging
  • Passive immunization

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. / Poduslo, Joseph F.; Ramakrishnan, Muthu; Holasek, Silvina S.; Ramirez-Alvarado, Marina; Kandimalla, Karunya K.; Gilles, Emily J.; Curran, Geoffry L.; Wengenack, Thomas M.

In: Journal of Neurochemistry, Vol. 102, No. 2, 07.2007, p. 420-433.

Research output: Contribution to journalArticle

Poduslo, Joseph F. ; Ramakrishnan, Muthu ; Holasek, Silvina S. ; Ramirez-Alvarado, Marina ; Kandimalla, Karunya K. ; Gilles, Emily J. ; Curran, Geoffry L. ; Wengenack, Thomas M. / In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. In: Journal of Neurochemistry. 2007 ; Vol. 102, No. 2. pp. 420-433.
@article{8e777021138d4f7190453ee6b96efbaf,
title = "In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques",
abstract = "Targeting therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood-brain barrier. We report that a F(ab′)2 fragment of a monoclonal antibody against fibrillar human Aβ42 that is polyamine (p)-modified has increased permeability at the blood-brain barrier, comparable binding to the antigen, and comparable in vitro binding to amyloid plaques in Alzheimer's disease (AD) transgenic mouse brain sections. Intravenous injection of the pF(ab′)24.1 in the AD transgenic mouse demonstrated efficient targeting to amyloid plaques throughout the brain, whereas the unmodified fragment did not. Removal of the Fc portion of this antibody derivative will minimize the inflammatory response and cerebral hemorrhaging associated with passive immunization and provide increased therapeutic potential for treating AD. Coupling contrast agents/radioisotopes might facilitate the molecular imaging of amyloid plaques with magnetic resonance imaging/positron emission tomography. The efficient delivery of immunoglobulin G fragments may also have important applications to other neurodegenerative disorders or for the generalized targeting of nervous system antigens.",
keywords = "Alzheimer's disease, Amyloid plaques, Antibody fragments, Contrast agent, Molecular imaging, Passive immunization",
author = "Poduslo, {Joseph F.} and Muthu Ramakrishnan and Holasek, {Silvina S.} and Marina Ramirez-Alvarado and Kandimalla, {Karunya K.} and Gilles, {Emily J.} and Curran, {Geoffry L.} and Wengenack, {Thomas M.}",
year = "2007",
month = "7",
doi = "10.1111/j.1471-4159.2007.04591.x",
language = "English (US)",
volume = "102",
pages = "420--433",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques

AU - Poduslo, Joseph F.

AU - Ramakrishnan, Muthu

AU - Holasek, Silvina S.

AU - Ramirez-Alvarado, Marina

AU - Kandimalla, Karunya K.

AU - Gilles, Emily J.

AU - Curran, Geoffry L.

AU - Wengenack, Thomas M.

PY - 2007/7

Y1 - 2007/7

N2 - Targeting therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood-brain barrier. We report that a F(ab′)2 fragment of a monoclonal antibody against fibrillar human Aβ42 that is polyamine (p)-modified has increased permeability at the blood-brain barrier, comparable binding to the antigen, and comparable in vitro binding to amyloid plaques in Alzheimer's disease (AD) transgenic mouse brain sections. Intravenous injection of the pF(ab′)24.1 in the AD transgenic mouse demonstrated efficient targeting to amyloid plaques throughout the brain, whereas the unmodified fragment did not. Removal of the Fc portion of this antibody derivative will minimize the inflammatory response and cerebral hemorrhaging associated with passive immunization and provide increased therapeutic potential for treating AD. Coupling contrast agents/radioisotopes might facilitate the molecular imaging of amyloid plaques with magnetic resonance imaging/positron emission tomography. The efficient delivery of immunoglobulin G fragments may also have important applications to other neurodegenerative disorders or for the generalized targeting of nervous system antigens.

AB - Targeting therapeutic or diagnostic proteins to the nervous system is limited by the presence of the blood-brain barrier. We report that a F(ab′)2 fragment of a monoclonal antibody against fibrillar human Aβ42 that is polyamine (p)-modified has increased permeability at the blood-brain barrier, comparable binding to the antigen, and comparable in vitro binding to amyloid plaques in Alzheimer's disease (AD) transgenic mouse brain sections. Intravenous injection of the pF(ab′)24.1 in the AD transgenic mouse demonstrated efficient targeting to amyloid plaques throughout the brain, whereas the unmodified fragment did not. Removal of the Fc portion of this antibody derivative will minimize the inflammatory response and cerebral hemorrhaging associated with passive immunization and provide increased therapeutic potential for treating AD. Coupling contrast agents/radioisotopes might facilitate the molecular imaging of amyloid plaques with magnetic resonance imaging/positron emission tomography. The efficient delivery of immunoglobulin G fragments may also have important applications to other neurodegenerative disorders or for the generalized targeting of nervous system antigens.

KW - Alzheimer's disease

KW - Amyloid plaques

KW - Antibody fragments

KW - Contrast agent

KW - Molecular imaging

KW - Passive immunization

UR - http://www.scopus.com/inward/record.url?scp=34347219429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347219429&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2007.04591.x

DO - 10.1111/j.1471-4159.2007.04591.x

M3 - Article

C2 - 17596213

AN - SCOPUS:34347219429

VL - 102

SP - 420

EP - 433

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 2

ER -